Please Wait

Applying Filters...

Technical details about Omeprazole Magnesium, learn more about the structure, uses, toxicity, action, side effects and more

Omeprazole Magnesium

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

31 Suppliers, 15 USDMF, 9 CEP/COS, 13 EU WC, 9 NDC API, 15 Listed Suppliers

DEVELOPMENTS

12 Drug(s) in Development

12 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

DOSSIERs // Finished Dosage Forms

33 Dossiers, 12 FDA Orange Book, 7 Europe, 13 Canada, 1 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE, FOR SUSPENSION, DELAYED RELEASE;ORAL - EQ 10MG BASE/PACKET, FOR SUSPENSION, DELAYED RELEASE;ORAL - EQ 2.5MG BASE/PACKET

RELATED EXCIPIENT COMPANIES

Suppliers, 25 BASF, 24 Kerry, 14 SPI Pharma, 14 Microlex e.U, 14 Corel Pharma Chem, 14 Roquette, 13 Gangwal Chemicals, 13 Ideal Cures Pvt Ltd, 13 Seppic, 9 Sigachi Industries, 8 Gangwal Healthcare, 7 Actylis, 6 Lonza Capsugel, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 ACG Worldwide, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 4 DKSH, 4 Rochem International Inc, 4 Nanjing Well Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 3 Kima Chemical, 3 Finar, 3 Prachin Chemical, 3 Doshion Polyscience, 3 Pharmatrans-Sanaq, 3 Evonik, 3 Alcedo Pharmachem, 3 DFE Pharma, 2 Seqens, 2 The Dow Chemical Company, 2 Vasa Pharmachem, 2 Jai Radhe Sales, 2 Qualicaps, 2 Pfanstiehl, 2 Nomisma Healthcare, 1 Vertellus, 1 Aeon Procare, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 NEWEDGE Overseas, 1 Chynops Pharma, 1 Pharm-RX Chemical, 1 Ingredion Pharma Solutions, 1 Nanjing Bold Chemical, 1 Ulanqab Kema New Material, 1 Minakem

EXCIPIENTS BY APPLICATIONS

67 Coating Systems & Additives, 53 Fillers, Diluents & Binders, 40 Controlled & Modified Release, 32 Direct Compression, 26 Thickeners and Stabilizers, 24 Solubilizers, 23 Taste Masking, 21 Lubricants & Glidants, 21 Disintegrants & Superdisintegrants, 18 Granulation, 16 Chewable & Orodispersible Aids, 16 Topical, 14 Parenteral, 14 Film Formers & Plasticizers, 13 Co-Processed Excipients, 9 Empty Capsules, 7 API Stability Enhancers, 7 Emulsifying Agents, 4 Vegetarian Capsules, 3 Surfactant & Foaming Agents, 3 Rheology Modifiers, 2 Coloring Agents, 1 Soft Gelatin

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 1 Finished Drug Prices

MARKET PLACE

2 APIs, 1 DOSSIERS // FDF

PATENTS

6 US Patents, 2 US Exclusivities, 38 Health Canada Patents

ANALYTICAL SOLUTION(s)

1 BioAnalytical Methods, 4 EDQM Standards, 1 USP Standards, 1 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilation & Company Tracker #PharmaFlow, 10 News

Also known as: Omeprazole magnesium, 95382-33-5, Magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole

Molecular Formula

C₃₄H₃₈MgN₆O₆S₂+₂

Molecular Weight

715.1 g/mol

InChI Key

ZAUIQBMEUIXDRJ-UHFFFAOYSA-N

A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole

2.1.2 InChI

InChI=1S/2C17H19N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3,(H,19,20);/q;;+2

2.1.3 InChI Key

ZAUIQBMEUIXDRJ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC.[Mg+2]

2.2 Synonyms

2.2.1 MeSH Synonyms

1. H 168 68

2. H 168-68

3. H 16868

4. Magnesium, Omeprazole

5. Omeprazole

6. Omeprazole Magnesium

7. Omeprazole Sodium

8. Prilosec

9. Sodium, Omeprazole

2.2.2 Depositor-Supplied Synonyms

1. Omeprazole Magnesium

2. 95382-33-5

3. Magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole

2.3 Create Date

2005-08-09

3 Chemical and Physical Properties

Molecular Formula	C₃₄H₃₈MgN₆O₆S₂+₂
Molecular Weight	715.1 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	10
Exact Mass	714.2144670 g/mol
Monoisotopic Mass	714.2144670 g/mol
Topological Polar Surface Area	193 Å²
Heavy Atom Count	49
Formal Charge	2
Complexity	453
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	2
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Omeprazole magnesium
Drug Label	11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret...
Active Ingredient	Omeprazole magnesium
Dosage Form	Capsule, delayed release
Route	Oral
Strength	eq 20mg base
Market Status	Over the Counter
Company	Dr Reddys Labs

2 of 2
Drug Name	Omeprazole magnesium
Drug Label	11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret...
Active Ingredient	Omeprazole magnesium
Dosage Form	Capsule, delayed release
Route	Oral
Strength	eq 20mg base
Market Status	Over the Counter
Company	Dr Reddys Labs

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Proton Pump Inhibitors

Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)

Anti-Ulcer Agents

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Proton Pump Inhibitor [EPC]; Proton Pump Inhibitors [MoA]; Cytochrome P450 2C19 Inhibitors [MoA]

POST ENQUIRY